Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 659 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Registered Dietitian vs. Nutritionist March 3, 2021 Treating the Whole Person: How Cancer Centers Are Addressing Social Needs July 18, 2024 Telehealth-Based Cancer Care Surged during COVID. Will It Continue? March 9, 2022 Searching for novel connections in cancer metabolism June 19, 2020 Load more HOT NEWS Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... Food for thought: new insights into how chemotherapy causes cachexia EMA Recommends Extension of Therapeutic Indications for Cabozantinib
